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Abstract 
Background: There has been an increase in the numbers of patients presenting to primary care with suspected colo-
rectal malignancy and subsequently an increase in demand for endoscopy. This study aims to forecast the cost of fae-
cal immunochemical testing (FIT) compared to conventional diagnostic tests as a primary investigation for patients 
with symptoms suggestive of colorectal malignancy.
Methods: Retrospectively, 1950 patients with symptoms suggestive of colorectal malignancy who were referred 
through primary care and underwent investigations through standard endoscopic evaluation were included. These 
patients were used to forecast the cost of faecal immunochemical testing creating theoretical data for sensitivity and 
specificity. Outcome measures included: the number of investigations under current protocol; cost of current investi-
gations; number of predicted false negatives and false positives and positive/negative predictive values using current 
sensitivity data for FIT; the cost forecast of using FIT as the primary investigation for colorectal malignancy.
Results: Median age was 65 (IQR 47–82) with 43.7% male and 56.3% female. A total of 1950 investigations 
were carried out with a diagnostic yield of 26 cancers (18 colon, 8 rectal), 138 polyps and 29 high risk adenomas 
(HGD ±  > 10 mm). In total, £713,948 was spent on the investigations. The commonest investigation was colonoscopy 
totalling £533,169. The total cost per cancer diagnosis was £27,459. Sensitivity (92.1% CI 86.9–95.3) and specificity 
(85.8% CI 78.3–90.1) for FIT in colorectal cancer was taken from NICE and was costed via the manufacturer(s). The 
projected total cost of FIT for the same population using a ≥ 4 μg haemoglobin cut off was £415,680 (£15,554 per 
cancer). The total cost of high-risk polyps using ≥ 4 μg cut off was £404,427 (sensitivity 71.2% CI 60.5–87.2, specificity 
79.8%CI 76.1–83.7) or £13,945 per polyp.
Conclusions: FIT is a cheaper and effective alternative test with the potential to replace current expensive methods. 
The forecast is based on the limited data available for sensitivity/specificity in the current literature. FIT has now been 
commenced for symptomatic patients in the UK and therefore sensitivity may change in the future.
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Introduction
Faecal Immunochemical Test (FIT) is a quick fae-
cel immunochemical test for Hb, designed to identify 
serious colorectal pathology. The test identifies small 
quantities of blood in the patient’s faeces (faecal occult 
blood (FOB)) using dedicated polyclonal antibodies to 
haemoglobin (Hb). Most colorectal pathology with the 
potential to become malignant tends to bleed more 
than native tissue. Therefore, the presence of blood in 
the faeces potentially indicates the presence of disease 
in the colon and/or rectum. Those who receive a posi-
tive FIT result precede to endoscopic investigation [1].
Currently, the standard protocol for patients present-
ing with symptoms associated with the lower gastroin-
testinal tract is investigation with endoscopy, thereby 
creating a large volume of requests for these services. 
A colonoscopy is an expensive, invasive procedure with 
significant risks and patient experience is often unfa-
vorable [2].
Secondary to increase in demand, endoscopy depart-
ments are struggling to meet the needs of the current 
referral system and it has been found many colonosco-
pies are being performed on large quantities of patients 
who are cancer free, questioning the need for change [3].
NICE Guidance DG30 [4] now recommends FIT 
should be used as a “straight to test” diagnostic tool for 
patients whose symptoms are suggestive of colorectal 
cancer. This paper is a cost forecast model for the use of 
FIT as an initial diagnostic tool prior to endoscopy or CT 
in symptomatic, two-week-wait (2WW) lower gastroin-
testinal (GI) referral patients.
Materials and Methods
Retrospective data was collected on all patients who 
presented to primary care with lower GI symptoms sug-
gestive of colorectal cancer who were urgently referred 
according to standardised 2WW criteria created by the 
Department of Health, UK and the National Institute of 
Health and Care Excellence (NICE) to Royal Liverpool 
University Hospital between March 2015 and November 
2017. Demographic details and specific referral bench-
marks from primary care were also documented.
Specialist nurses at the Royal Liverpool University 
Hospital who had received detailed training on the pro-
cess triaged the referrals and categorised patients into 
different groups for investigation. Referral criteria can 
be seen in Additional file  1. All patients could qualify 
for more than one group. All patients who underwent 
investigation were sent bowel preparation by post with 
information about the colonoscopy procedure. Individ-
ual suitability for the test was confirmed on the day by 
assessment by the endoscopist on a ‘case by case’ basis.
One HM-JACKarc analytical system (Kyowa Medex/
Alpha Labs) was The FIT method used for all samples. 
The analytical working range was 2–8000 µg Hb/g faeces 
(µg/g). The limit of detection of the assay is 2 µg/g and the 
limit of quantification was 100 µg/g. Positivity was deter-
mined at 4 µg/g and classified into amber (4-10 µg/g) and 
red (> 10  µg/g). FITTER guidelines for reporting were 
used according to Fraser et al. [5].
Patients with normal tests were immediately dis-
charged. Any positive findings were then reviewed by 
senior clinicians and it was decided at this point whether 
the patient a) was discharged, b) was sent for further 
investigations or treatment, or c) brought to clinic to 
discuss findings. Any patients who were deemed to have 
either an equivocal diagnosis or positive cancer diagnosis 
were referred to the local multi-disciplinary team (MDT) 
meeting for further management.
From collected data, a reverse cost forecast analy-
sis was performed using sensitivity/specificity methods 
by Westwood et al. [6]. This data was then used to esti-
mate false positives, false negatives, the positive predic-
tive value (PPV) and the negative predictive value (NPV) 
that would have likely been in our population of patients 
if we had used FIT as the primary investigation. These 
values were then used to forecast the cost of FIT com-
pared to the current protocol using the following calcula-
tion: true negatives x cost of one FIT + (true positives x 
cost of colonoscopy) + (false positives x cost of colonos-
copy) + (false negatives x cost of colonoscopy). Data was 
analysed and results were derived using SPSS 24 (IBM, 
Armonk, New York, USA).
Results
A total of 1950 patients were triaged through our ser-
vice with a sex bias of, male (43.7%) and female (56.3%). 
Patient demographics included in the study are displayed 
in Table 1 below.
Median age of referral was 65 with a median local pop-
ulation age of 70. As expected, the main modalities of 
Table 1 Patient demographics
Demographics
Total Number of Patients 1950
Number of Males 852
Number of Females 1098
Median Age (interquartile range) 65.00 (47–82)
Median Age for Males (interquartile range) 65.00 (49–76)
Median Age for Females (interquartile range) 65.00 (47–82)
Average Pathway Duration 63.01
SD for Pathway Duration 45.59
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investigation were endoscopic (colonoscopy and flexible 
sigmoidoscopy) and radiological (CT colonography) with 
some patients undergoing aditional gastroscopy due to 
national guidelines for iron deficiency anaemia. The dis-
tribution of these investigations are shown in Fig. 1.
Patients were coded and categorised to one or more 
groups depending on their symptoms. The highest num-
ber of patients were found in the > 50  years group and 
with a change in bowel habit (looser faeces ± more fre-
quent movements) (n = 754). There were no patients who 
coded into the < 50 years group with rectal bleeding and 
weight loss and no patients with a positive FOB screen-
ing referral. This was expected as they are investigated 
through a separate pathway.
The most common diagnosis was diverticular disease 
with a total of 474 patients. This was followed by ulcera-
tive colitis (n = 39). A total of 26 cancer diagnoses were 
found, of which 18 (69%) were colon cancer and 8 (31%) 
were rectal cancer. There were 1323 patients with no 
diagnosis after investigation and were deemed normal/
none-serious results and discharged. These figures are 
represented in Fig. 2.
A total of 1950 investigations were conducted which 
reported the finding of 26 cancers (approximately one 
cancer per 90 investigations) and 29 high-risk polyps 
(> 10 mm ± high grade dysplasia) resulting in a 2.7% yield 
of significant neoplasia. Figure 3 shows the total cost of 
investigations that took place. These were calculated 
using the tariffs released by the NHS for 2018/19. Natu-
rally, the most significant cost is colonoscopy, which had 
the greatest number of patients (n = 1323) at a single test 
cost of £403 (£465 with biopsy). This was followed by CT 
colonography (n = 591) at a cost of £196 per scan. Flexi-
ble sigmoidoscopy (n = 252) cost £310 per test (£372 with 
biopsy) and finally gastroscopy (n = 178) at £341 per test 
(£388 with biopsy).
Tables  2 and 3 show the sensitivity and specificity of 
FIT at each of the Hb cut off values and the predicted 
false positives and false negatives modelling our popula-
tion on FIT for CRC and high-risk polyps. The data was 
generated using the actual results obtained in the retro-
spective analysis and the predicted cost was calculated 
using the current sensitivity/specificity data used by 
NICE.
For the current protocol, £713,948 was spent in 
this study on investigations with colonoscopy costing 
£533,169 alone. The endoscopic/radiological evaluation 
for each cancer was £27,459 and £24,618 for high-risk 
polyps.
Depending upon manufacturer, FIT is significantly 
cheaper at £5 per test [7]. We forecasted the cost of 
using FIT as a primary investigation on our population 
using ≥ 4  μg Hb cut off with the following calculation 
(1895 x £5 + (true positives x £465) + (false positives x 
£465) + (false negatives x £465)). The total cost of FIT 
would have been £404,427, equating to £ 15,554 per can-
cer. The total cost of high-risk polyps using ≥ 4 μg cut off 
level was £13,945 per polyp.
Discussion
Colorectal malignancy (CRC) is one of the top three 
most common cancers in the UK but is considered to 
be very treatable due to recent improvements in early 
detection [8]. FIT testing was originally developed as 
Fig. 1 The distribution of investigations as per the current protocol
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an advancement on guaiac Faecal Occult Blood testing 
in bowel cancer screening. It is designed to detect small 
amounts of blood in faeces using polyclonal antibodies 
to the Hb molecule [9]. Recent evidence has found with 
some certainty that the use of quantitative faecal immu-
nochemical testing has substantial benefits over the FOB 
test in both accuracy and compliance [10]. This posed the 
question of whether FIT could be used as a primary diag-
nostic test rather than only for screening.
With rising awareness of CRC in the population, there 
has been an increase in the numbers of patients presenting 
to primary care with symptoms suggestive of CRC. This, 
coupled with a change in NICE guidance, resulted in more 
referrals to secondary care for 2WW cancer referrals and 
so in turn escalated the demand for colonoscopies [11].
If the current trend continues, Bowel Cancer UK esti-
mates that there will be an increase in demand of 10–15% 
per year for diagnostic colonoscopies [8]. Endoscopy ser-
vices are already stretched to capacity with the increas-
ing demand and many patients breach the recommended 
2WW for investigation. Secondly, endoscopic evaluation 
of the bowel is not without risk and carries a false nega-
tive rate of approximately 5% [12]. In addition, endosco-
pies are expensive and can be an unpleasant experience 
for patients.
In an attempt to streamline the referral system, initia-
tives have been created in some units such as nurse led 
colorectal telephone assessment pathways and the so 
called ‘straight to test’ pathway. These systems have been 
shown to reduce the time it takes for investigations to be 
Fig. 2 Distribution of diagnosis
Fig. 3 Cost breakdown of the investigations in the current protocol
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carried out, but studies have revealed that patients may 
still be subject to inappropriate investigations for their 
symptoms, especially due to a lack of early assessment 
[13]. Thus, the identification of a cheaper, well tolerated 
investigation that has a robust sensitivity is of upmost 
importance. FIT has the potential to be used at the point 
of referral from primary care to guide the need for fur-
ther investigations, reduce unnecessary colonoscopies 
and create a more cost-effective system. Despite this, it is 
important to consider the detection and removal of pol-
yps during colonoscopy which reduces future CRC inci-
dence and mortality.
When looking at Hb cut off values in faecal immu-
nochemical testing, increasing the Hb cut-off decreases 
the sensitivity, decreases the specificity of the test and 
increases the number of false negatives. Using FIT 
with an Hb cut off of 4 μg Hb/g in our population, the 
number of false negatives would be 0.8. Although this 
is low, the acceptability of this rate on a larger scale 
must be considered. We forecast that any missed can-
cers would develop further symptoms and therefore 
represent at a later date. These theoretical patients with 
more advance disease have their own cost implications 
and more importantly the ethical implications associ-
ated with a missed cancer diagnosis. Robust safety net-
ting advice for patients using FIT would be absolutely 
necessary.
Patients receiving negative FIT test results could 
be reassured they are unlikely to have cancer and dis-
charged. Other possible outcomes of a negative FIT could 
be watch and wait, onward referral to colorectal outpa-
tient clinic or repeat faecal immunochemical testing, par-
ticularly if the patient’s symptoms persist. It is vital that 
FIT results should not be viewed in isolation and clini-
cal judgement remains of paramount importance. Results 
for high-risk polyps shows a reduced sensitivity/specific-
ity and a higher false negative rate of 11 at the 4 μg Hb/g 
cut off and these would also have the possibility of missed 
malignancy.
Using a Hb cut-off of 4 μg Hb/g determined 258 false 
positives. This can be explained as FIT detects haemoglo-
bin associated with a variety of other pathology such as 
inflammatory bowel disease [14]. Data from other studies 
suggested that up to 28.9% of patients with an initial false 
positive result from a FIT were eventually diagnosed with 
some form of serious bowel disease [15]. In our forecast, 
the patient who received a positive result would undergo 
colonoscopy as per the protocol and therefore patient 
disruption would be minimal.
Overall, the results of this study are positive and 
reveal a highly sensitive and specific test that could 
be used as a primary investigation for 2WW patients 
to facilitate the saving of colonoscopy resources. 
The cost of endoscopy to NHS England in 2014 was 
approximately £178.4 million and it was found that 
approximately 40% of tests were normal [16] which is 
comparable to our study. This study shows the cost of 
diagnosing colorectal cancer and high-risk polyps via 
endoscopy is significantly higher than the forecasted 
cost of FIT at £27,459 and £24,618 vs £15,554 and 
£13,945 respectively. This is a potential cost reduction 
of 43% over 2 years (£309,521).
Conclusion
FIT is likely to be a cheaper alternative diagnostic than 
current methods with similar sensitivity and could 
potentially be used to replace the former, however, fur-
ther studies pertaining to sensitivity and specificity are 
necessary.
Table 2 FIT sensitivities/specificities at various Hb cut offs and modelling data for CRC 
Hb Threshold Sensitivity 95% CI Specificity 95% CI True + True - False + False - PPV (%) NPV 
(%)
4 μg 97.2 85.5–99.9 88.4 58.1–92.7 26 1895 258 0.8 2 99.9
10 μg 92.1 86.9–95.3 85.8 78.3–90.1 26 1895 314 2 7.5 99.8
15 μg 92.3 86.6–96.1 86.9 85.6–88.1 26 1895 286 2 8.2 99.8
20 μg 89.5 84.9–93.1 86.6 85.4–87.7 26 1895 293 3 8 99.8
Table 3 FIT sensitivities/specificities at various Hb cut offs and modelling data for high-risk polyps
Hb Threshold Sensitivity 95% CI Specificity 95% CI True + True - False + False - PPV (%) NPV 
(%)
4 μg 71.2 60.5–87.2 79.8 59.7–88.1 29 1895 503 11 6 99.2
10 μg 68.9 53.2–81.4 80.2 76.1–83.7 29 1895 468 13 7 99.2
15 μg 66.7 50.9–79.6 83.1 79.2–86.5 29 1895 385 14 7 99.3
20 μg 64.4 48.7–77.7 85.7 81.9–88.7 29 1895 316 16 8 99.1
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